References

R&D, Scientific & Medical Writing

• Supporting global pharmaceutical company in medical writing of briefing books and INDs, 2021-present.
• German company in bioinformatics and data analytics in cancer, 2016-present: abstracts, papers
• Finish preclinical CRO, 2017-2020: assistance in writing reports, advice on internal projects, member Steering Group
• LibraMedicina, Inc. Japan, 2007-present: search potential licensees for anticancer drugs in preclinical stage
• Meeting Report CDDF Multi-stakeholder workshop on Impact of the Microbiome on Cancer Growth and Therapy, February 2019
• Meeting Report on the CDDF Multi-stakeholder Workshop Innovation in Oncology Clinical Trial Design, 2017 and the subsequent paper 2019, https://doi.org/10.1016/j.ctrv.2019.01.001

• Recent publications
  • Vincent Vuaroqueaux, Hans Hendriks, Hoor Al-Hasani, Anne-Lise Peille, Samayita Das, and Heinz-Herbert Fiebig. Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. npj Precision Oncology 2021;5(1):96. https://doi.org/1038/s41698-021-00235-7
  • Verweij J, Hendriks HR, Zwierzina H, on behalf of the Cancer Drug Development Forum. Innovation in Oncology Clinical Trial Design. Cancer Treatment Reviews 2019;74:15-20, https://doi.org/10.1016/j.ctrv.2019.01.001
  • Peters GJ, Govaerts A-S, Hendriks HR, for the EORTC-PAMM group. The Role of Pharmacology in Anticancer Drug Development. ADMET & DMPK 2018;6:4-14
  • Hendriks et al, Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds inititative, British Journal of Cancer 2017;117:195-202
  • Quandt et al, Implementing liquid biopsies into clinical decision making for cancer immunotherapy, Oncotarget 2017;8:48507-48520
  • Phillips et al, Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer, Expert Opinion on Drug Metabolism &Toxicology 2017;13:783-791
• Recent lectures
  
  • Hendriks HR. Preclinical drug development in oncology. Educational lecture, Finnish prclinical CRO, December 2019
  • Hendriks HR. Drug development, after the NCI-compounds initiative. Educational course: preclinical and early-phase clinical pharmacology. 40^th EORTC-PAMM Winter meeting, Verona, 6 February, 2019.
  • Hendriks HR. New Types of Clinical Studies. Educational course: Preclinical and early-phase clinical pharmacology. 40th EORTC-PAMM Winter meeting, Verona, 6 February, 2019.
  • Hendriks HR. Pharmacology directed strategies in anticancer drug development, a viable approach for academia? Turku Cancer Research Society & Western Cancer Centre FICAN West, Cancer Seminar Series, Turku, Finland, 4 September 2018.